Atrion (NASDAQ:ATRI) Sees Large Volume Increase

Atrion Co. (NASDAQ:ATRI - Get Free Report) shares saw an uptick in trading volume on Thursday . 8,248 shares changed hands during trading, a decline of 38% from the previous session's volume of 13,347 shares.The stock last traded at $449.40 and had previously closed at $448.00.

Analysts Set New Price Targets

Separately, StockNews.com raised Atrion from a "sell" rating to a "hold" rating in a research note on Friday, March 1st.

Atrion Trading Up 3.5 %

The company has a 50 day simple moving average of $375.93 and a 200-day simple moving average of $367.15. The stock has a market cap of $815.85 million, a price-to-earnings ratio of 41.34 and a beta of 0.58.

Atrion (NASDAQ:ATRI - Get Free Report) last released its quarterly earnings results on Thursday, February 29th. The medical instruments supplier reported $3.65 earnings per share (EPS) for the quarter. Atrion had a return on equity of 8.07% and a net margin of 11.46%. The firm had revenue of $43.58 million for the quarter.

Atrion Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 29th. Shareholders of record on Friday, March 15th will be paid a $2.20 dividend. This represents a $8.80 annualized dividend and a dividend yield of 1.90%. The ex-dividend date of this dividend is Thursday, March 14th. Atrion's dividend payout ratio is 79.78%.

Institutional Trading of Atrion

Hedge funds and other institutional investors have recently modified their holdings of the stock. Copeland Capital Management LLC increased its position in shares of Atrion by 56.4% in the fourth quarter. Copeland Capital Management LLC now owns 86 shares of the medical instruments supplier's stock valued at $33,000 after acquiring an additional 31 shares during the last quarter. Quadrant Capital Group LLC acquired a new stake in shares of Atrion in the fourth quarter valued at about $36,000. FMR LLC grew its holdings in Atrion by 38.0% during the first quarter. FMR LLC now owns 69 shares of the medical instruments supplier's stock worth $43,000 after purchasing an additional 19 shares during the period. Qube Research & Technologies Ltd bought a new position in Atrion during the third quarter worth about $60,000. Finally, Advisor Group Holdings Inc. bought a new position in Atrion during the fourth quarter worth about $65,000. Institutional investors and hedge funds own 66.19% of the company's stock.

Atrion Company Profile

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.